Wedbush reissued their outperform rating on shares of Stemline Therapeutics Inc. (NASDAQ:STML) in a research report released on Tuesday morning. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on STML. Zacks Investment Research downgraded shares of Stemline Therapeutics from a buy rating to a hold rating in a research note on Tuesday, July 12th. Jefferies Group reissued a buy rating and issued a $23.00 price target on shares of Stemline Therapeutics in a research note on Friday, July 22nd. Finally, Roth Capital reissued a buy rating and issued a $32.00 price target on shares of Stemline Therapeutics in a research note on Thursday, August 25th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $20.50.

Stemline Therapeutics (NASDAQ:STML) opened at 11.95 on Tuesday. The stock’s 50 day moving average is $11.60 and its 200 day moving average is $8.38. Stemline Therapeutics has a one year low of $3.88 and a one year high of $14.20. The firm’s market cap is $213.01 million.

Several institutional investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. purchased a new position in Stemline Therapeutics during the first quarter worth about $232,000. Carl Domino Inc boosted its position in Stemline Therapeutics by 12.9% in the second quarter. Carl Domino Inc now owns 26,305 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,000 shares during the last quarter. California State Teachers Retirement System boosted its position in Stemline Therapeutics by 6.1% in the second quarter. California State Teachers Retirement System now owns 35,349 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 2,019 shares during the last quarter. Emerald Acquisition Ltd. purchased a new position in Stemline Therapeutics during the second quarter worth about $129,000. Finally, Nationwide Fund Advisors boosted its position in Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 8,670 shares during the last quarter. Hedge funds and other institutional investors own 52.60% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.